-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anti-CD19 CAR-T cells are a representative major advance
in the treatment of relapsed/refractory aggressive B-cell lymphoma.
However, a large number of patients have failed treatment
.
Of the 550 patients registered with DESCAR-T in France, 238 (43.
3%) experienced progression/relapse, with a median follow-up of 7.
9 months
.
At the time of registration, 57.
0% of patients had an age-adjusted international prognostic index of 2-3, 18.
9% of patients had an ECOG manifestational status ≥2 points, 57.
1% of patients had received >3-line therapy before receiving CAR T cells, and 87.
8% had bridging therapy
.
When CAR-T cells were infused, 66% of patients showed progressive disease and 38.
9% had high lactate dehydrogenase (LDH) levels
.
The median time to failure of CAR T cell therapy was 2.
7 months (range: 0.
2-21.
5 months
).
54 (22.
7%) patients experienced very early failure (within 30 days); 102 (42.
9%) patients experienced early failure (day 31 to 90 days) and 82 (34.
5%) experienced late failure (after 90 days
).
Objective remission rate for salvage therapy
After treatment failure, 154 (64%) patients received salvage therapy; 38.
Total survival is grouped according to treatment failure time
The median progression-free survival was 2.
Overall, at the 6th month, 47.
Original Source:
Di Blasi Roberta,Le Gouill Steven,Bachy Emmanuel et al.
